Gefitinib
- PDF / 130,970 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 65 Downloads / 169 Views
1
S
Rashes: case report A 58-year-old man developed rashes while receiving gefitinib. The man presented with a cough and lower extremity pain, and was diagnosed with primary non-small cell lung cancer (NSCLC) with multiple bone metastases. After chemotherapy with cisplatin and gemcitabine, disease progression was confirmed with multiple pulmonary metastasis and brain metastasis. He started oral gefitinib 250mg once daily. After 3 weeks, his cough and pain, as well as his metastatic lesions, had improved. At this time, he had multiple and scattered acneiform eruptions with mild itching in his orofacial and chest region. On the 36th day, he had severe skin rashes appearing extensively. The diffuse painful erythema and oedema on his upper extremity were so serious that they affected his daily activities. The manifestations of the rash were diverse, including erythema, acneiform rash, pustular rash and local crusting, with some sites showing lichenoid changes. Gefitinib-induced skin injury was suspected. Gefitinib was withdrawn, and the man received combined therapies, including loratadine and ethacridine. After 1 week, his symptoms were significantly relieved, and his rashes subsided gradually. After 1 month, the rashes disappeared, with no obvious pigmentation, and only a little crusting scattered on his limbs. However, a chest CT showed enlargement of his metastatic lesions. The man restarted gefitinib 250mg once daily. After 1 month, he had a little acneiform rash scattered on the side of his nose with a mild itch, but no rashes on his body or extremities. His metastatic lesions diminished. Author comment: "[W]e reported a case with NSCLC, who suffered severe dermatologic [adverse effects] related with gefitinib". Li Y-Q, et al. A severe dermatologic adverse effect related with gefitinib: case report and review of the literature. Journal of Cancer Research and Therapeutics 9 (Suppl. 2): S110-S113, No. 5, Sep 2013. Available from: URL: http:// 803095572 dx.doi.org/10.4103/0973-1482.119123 - China
0114-9954/13/1477-0001/$14.95 Adis © 2013 Springer International Publishing AG. All rights reserved
Reactions 9 Nov 2013 No. 1477
Data Loading...
